Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis
- 27 January 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (2)
Abstract
Maraviroc-based regimens have been explored as preexposure prophylaxis (PrEP) against human immunodeficiency virus (HIV). In this study, we utilized mucosal tissue drug exposure data, combined with target concentrations generated in vitro , in a pharmacokinetic-pharmacodynamic analysis to predict the effects of drug combinations and adherence on PrEP efficacy. Mucosal tissue concentrations of maraviroc were measured in 24 healthy women.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (U01 AU095031)
- HHS | NIH | National Institute of General Medical Sciences (T32 GM086330)
- UNC | UNC-CH | Center for AIDS Research, University of North Carolina at Chapel Hill (P30 AI50410)
This publication has 31 references indexed in Scilit:
- Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2012
- Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative MenThe Journal of Infectious Diseases, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse ModelPLOS ONE, 2010
- Protection of Rhesus Macaques from Vaginal Infection by Vaginally Delivered Maraviroc, an Inhibitor of HIV‐1 Entry via the CCR5 Co‐ReceptorThe Journal of Infectious Diseases, 2010
- Maraviroc modelling strategy: use of early phase 1 data to support a semi‐mechanistic population pharmacokinetic modelBritish Journal of Clinical Pharmacology, 2009
- Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Handling Data Below the Limit of Quantification in Mixed Effect ModelsThe AAPS Journal, 2009
- A population pharmacokinetic meta‐analysis of maraviroc in healthy volunteers and asymptomatic HIV‐infected subjectsBritish Journal of Clinical Pharmacology, 2008
- Pharmacodynamic Interaction of Recombinant Human Interleukin-10 and Prednisolone Using in vitro Whole Blood Lymphocyte ProliferationJournal of Pharmaceutical Sciences, 2002